Skip to content
Screener

Gilead Sciences GILD Tecartus — Total revenues

Other product segments

Biktarvy
$3.77B+6.9%
Descovy
$967M+48.1%
Trodelvy
$457M+25.5%
Yescarta
$346M-12.0%
Sofosbuvir/Velpatasvir
$303M-11.4%
Genvoya
$289M-23.3%
Vemlidy
$289M+14.7%
Odefsey
$239M-19.8%
Yeztugo
$232M+1,447%
Royalty, contract and other revenues
$176M+552%
Livdelzi
$167M+114%
Symtuza - Revenue share
$138M+11.3%
Other Liver Disease
$118M-4.1%
AmBisome
$110M-14.7%
Other HIV
$56M-39.1%
Other
$51M-30.1%
Veklury
$23M-81.0%

Similar metrics at other companies

Sonida Senior Living logo
SNDAResident revenue — Total revenues
$108.43M+36.8%
Asset Entities logo
ASSTOther revenue — Total revenues
$43K+514%
ALN
ALNYRoyalty revenue — Total revenues
$71.67M+79.3%
Hyatt Hotels logo
HContra revenue — Total revenues
-$17M-13.3%
FTAI Aviation Ltd. logo
FTAIMaintenance revenue — Total revenues
$30.6M-38.3%
FTAI Aviation Ltd. logo
FTAIOther revenue — Total revenues
$6.21M+19,923%

Other financials

Income statement

See full
Revenue$7.8B+10.2%
Gross profit$6.2B+11.5%
Operating income-$10.4B-520%
Net income-$10.5B-636%
EPS (diluted)-$8.45-642%

Balance sheet

See full
Cash & equivalents$3.2B-38.2%
Total debt$26.2B+5.2%
Total equity$11.8B-39.9%
Total assets$49.4B-11.4%

Cash flow

See full
Operating cash flow$3.6B+332%
CapEx$140.0M+30.8%
Free cash flow$3.4B+377%

Valuation

See full
Market cap$163.59B+19.3%
Enterprise value$186.66B+18.9%
P/S5.4×+0.6×

Profitability

See full
Gross margin79.6%+1.1pp
Operating margin-8.2%-36.1pp
Net margin-10.6%-32.5pp
FCF margin42.5%+10.0pp

Returns & leverage

See full
Return on equity-20.6%-53.8pp
Debt / equity2.2×+1.0×
Current ratio1.3×0.0×

Where this comes from

Reported directly by Gilead Sciences in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Gilead Sciences’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:13 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000882095-26-000031
(in millions)Three Months Ended June 30, 2026 / U.S.Three Months Ended June 30, 2026 / EuropeThree Months Ended June 30, 2026 / Rest of WorldThree Months Ended June 30, 2026 / TotalThree Months Ended June 30, 2025 / U.S.Three Months Ended June 30, 2025 / EuropeThree Months Ended June 30, 2025 / Rest of WorldThree Months Ended June 30, 2025 / Total
Veklury142723511950121
Oncology
Cell Therapy
Tecartus29348704141992
Yescarta1321397534616215477393
Total Cell Therapy1611738341720319686485
Trodelvy30792574572249644364
Total Oncology468265140873427291131849

Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FAQ

What is Gilead Sciences's tecartus — total revenues?
Gilead Sciences (GILD) reported tecartus — total revenues of $70M in Q2 2026.
How has Gilead Sciences's tecartus — total revenues changed year-over-year?
Gilead Sciences's tecartus — total revenues decreased by 23.9% year-over-year, from $92M to $70M.
What is the long-term trend for Gilead Sciences's tecartus — total revenues?
Over 4 years (2021 to 2025), Gilead Sciences's tecartus — total revenues has grown at a 18.2% compound annual growth rate (CAGR), from $176M to $343M.
What does tecartus — total revenues mean?
This metric represents the total gross sales generated from the commercialization of a specific cell therapy product line. It reflects the market adoption and therapeutic demand for this specialized oncology treatment within the company's broader cell therapy portfolio. Monitoring these revenues helps assess the product's lifecycle performance and its contribution to the company's overall oncology segment growth.

Ask your AI about Gilead Sciences's tecartus — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude